Elevated PSA: Causes Other Than Prostate Cancer and What Next

PSA is an enzyme made by cells of the prostate gland, a small amount of which passes into the blood. Any process that increases the number of prostate cells, damages their barrier or irritates the gland can raise the blood concentration of PSA. Cancer is one such process, but by no means the only one — nor even the most common. That is why a result above the laboratory range is often the start of a conversation with a urologist, not its end.

This article covers exactly the non-malignant causes of an elevated PSA and how doctors tell them apart from changes that need a biopsy. It does not settle the debate on the value of mass screening — we devote a separate text to that controversy — and it does not describe the treatment of prostate cancer. Information about the test itself, its interpretation and its role in diagnosis can be found in the entry on PSA and the prostate in our knowledge base.

The key thing is to keep a sense of proportion. On the one hand, most men with a slightly raised PSA do not have cancer, so panic makes no sense. On the other hand, you must not reassure yourself only with the phrase 'it's probably just enlargement', because both situations sometimes coexist. It is therefore sensible to take transient factors out of the equation, repeat the test and — if the result persists — use today's tools, above all prostate magnetic resonance imaging.

PSA is a protein that liquefies semen. In the prostate it is found in an enormous concentration, and in the blood in amounts roughly a million times smaller. Under normal conditions the structure of the gland, with its fine ducts and a barrier between the lumen and the blood vessels, limits the passage of PSA into the blood. When this structure is disturbed, PSA passes through more easily and its blood concentration rises.

There are three main routes to a higher PSA. The first is a larger mass of gland: the more prostate tissue, the more PSA, which explains the rise with age and with benign enlargement. The second is damage to or irritation of the barrier — by inflammation, injury, a procedure, ejaculation or pressure. The third is changes in the cellular architecture itself, including a tumor, in which PSA passes into the blood more readily. The first two routes are far more common, but neither is a 'signature' of a particular disease.

In the blood PSA exists in two forms: bound to proteins and free. The ratio of free to total PSA can be helpful, because in cancer the percentage of free PSA is usually lower, and in benign conditions such as BPH higher. It is, however, an auxiliary tool, especially useful in the so-called gray zone of results, rather than a stand-alone deciding test.

The factors listed can occur together. A man with an enlarged prostate over 60 who had intercourse and went cycling the day before the draw may have an inflated result for three reasons, none of which is related to cancer. That is why it is so important to repeat the test under standardized conditions.

A classic 1995 study tried to answer a practical question: why is PSA clearly elevated in some men even though repeated biopsies show no cancer? The authors compared two groups of men with multiple negative biopsies and a suspicious digital rectal exam.

A practical conclusion follows from this work: a large gland and subclinical inflammation 'explain' a considerable part of PSA elevation in men without cancer. Inflammation can also be asymptomatic — it need not cause pain or fever, yet it still raises PSA. This is why the doctor asks about urinary symptoms, history of infections and prostate volume (assessed on ultrasound or MRI). You can read more about enlargement, its symptoms and treatment in the entry on benign prostatic hyperplasia.

It is worth remembering a limitation, however: explaining a PSA rise by inflammation or enlargement does not remove the need for further assessment if the result is high or rising. Both situations can coexist with cancer, and the mere fact that the prostate is large does not exclude a lesion within the gland that needs a biopsy. That is why indicators such as PSA density, free PSA and the MRI picture are so valuable.

Transient factors are the easiest group of causes to control: they can be avoided or at least you can wait until their effect passes. The best documented is the effect of ejaculation.

In practice many urologists advise abstaining from intercourse and masturbation for several days before the draw, to be sure that ejaculation does not disturb the result. Likewise it is worth avoiding intensive cycling immediately before the test, although reviews of the research on this have not given unambiguous results — some papers showed a PSA rise after prolonged riding, others found no effect, and the samples were usually small. A sensible compromise is simply a day or two without the bike.

A digital rectal exam performed by the doctor, according to most sources, affects PSA only slightly, but by convention blood is drawn before it if both examinations are planned on the same day. Biopsy, cystoscopy or catheterization raise PSA for longer, so after such procedures a repeat PSA is usually planned after a few weeks. A urinary tract infection should be cured before the result is interpreted; routine 'treatment just in case' with an antibiotic without symptoms of infection is not widely recommended and is worth discussing with a urologist.

For years 4 ng/mL was regarded as the borderline value, but the modern approach holds that risk is continuous and depends on age, prostate volume, family history and additional indicators. In younger men typical concentrations are low — in one German population study of men without prostate disease (median age 46) median PSA was around 0.8 ng/mL, and values rise with age along with gland volume. Often-quoted, approximate upper limits increase from about 2.5 ng/mL in the fourth decade of life to about 6.5 ng/mL in the eighth, but these are not rigid rules and differ between sources.

PSA density is the PSA concentration divided by prostate volume. The idea is simple: a large gland 'is entitled' to produce more PSA, so the same concentration in a small prostate is more worrying than in a large one. Low density (in practice a threshold of about 0.15 ng/mL per mL is often taken as a guide) argues for a benign cause, and high density for further workup. Calculating it requires a reliable volume estimate, which transrectal ultrasound or MRI provide, which is why these tests matter so much here.

Free PSA is most useful when total PSA falls in the gray zone, roughly 4–10 ng/mL. A low percentage of free PSA (approximately below 10–15%) is associated with a greater probability of cancer, and a high one (above about 25%) with a greater probability of a benign cause. Like other indicators, free PSA is not a final verdict, but helps decide whether further workup is urgent.

A separate matter is drugs. 5-alpha-reductase inhibitors (finasteride, dutasteride), used in prostate enlargement, lower PSA by roughly half within about a year, which means the true result has to be interpreted after multiplying by a correction factor (usually about 2). Testosterone therapy, on the other hand, can raise PSA somewhat, and PSA monitoring is a standard part of follow-up. Your doctor must be told about every drug you take before the result is interpreted.

If after eliminating transient factors PSA is still elevated or rising, the standard in many centers today is prostate magnetic resonance imaging before a biopsy. It lets you assess prostate volume and, above all, point to areas suspicious for clinically significant cancer that can be targeted during the biopsy — or, when the picture is reassuring, avoid a biopsy altogether. We describe the examination in the entry on magnetic resonance imaging, and diagnosing enlargement and assessing volume on ultrasound in the entry on ultrasonography.

For a reader worried about an elevated PSA, one thing follows: the modern pathway is gentler and less invasive than it used to be. MRI can serve as a 'filter' that lets some men avoid a biopsy, and if a biopsy is needed it can be done more accurately. This does not mean MRI is infallible — in PROMIS its specificity was 41%, so a suspicious image does not equal cancer. The decision on next steps is made together with a urologist, on the basis of the whole picture: PSA, its dynamics, PSA density, prostate volume, digital rectal exam and the MRI result.

There is also the opposite myth: 'PSA is normal, so I definitely do not have cancer'. The truth is that some prostate cancers develop with a low PSA, and a single value does not replace assessment of the whole, including the digital rectal exam, family history and the trend of results over time. For men in higher-risk groups (prostate cancer in a father or brother, BRCA gene mutations) closer surveillance may be sensible.

A third misunderstanding concerns ways of 'lowering PSA'. Supplements advertised as lowering PSA have no solid evidence, and using them can mask changes and delay diagnosis. If PSA is raised, the right response is to establish the cause, not to try to lower the number itself.

The symptoms listed more often result from benign causes but need assessment. On the other hand, the absence of symptoms does not mean everything is fine — early prostate cancer usually produces none. That is why the decision about surveillance rests on PSA, age and risk factors, not on how you feel alone.

An elevated PSA is a result that deserves a calm, methodical response. First we eliminate transient factors and repeat the test, then we assess prostate volume, PSA density and the free fraction, and if the result still raises doubts, we use MRI before any biopsy. In most cases enlargement or inflammation is behind the rise, and modern diagnostics make it possible to avoid unnecessary procedures without missing real lesions.